San Diego, California-based Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression.

The pipeline includes cirmtuzumab, a monoclonal antibody in Phase I/II development that inhibits the ROR1 receptor in various hematologic cancers; TK-216, a small-molecule in Phase I development that inhibits ETS-family oncoproteins, as a treatment for Ewing sarcoma, a rare pediatric cancer; and a CAR-T therapy that targets ROR1 currently in preclinical development as a potential treatment for solid tumors and hematologic cancers.